



Market Announcement

25 May 2020

Prescient Therapeutics Limited (ASX: PTX) – Suspension from Official Quotation

Description

The securities of Prescient Therapeutics Limited ('PTX') will be suspended from quotation immediately under Listing Rule 17.2, at the request of PTX, pending the release of an announcement regarding a material licence agreement.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

25 May 2020

Attention: Melissa Kostopoulos
Compliance Adviser, Listings Compliance
Level 4, North Tower, 525 Collins Street
Melbourne VIC 3000

By email only: melissa.kostopoulos@asx.com.au

Dear Melissa,

REQUEST FOR VOLUNTARY SUSPENSION

Prescient Therapeutics Limited (ASX: **PTX**) (the “**Company**”) requests an immediate suspension of the Company’s ordinary shares quoted on the Australian Securities Exchange (“ASX”) in accordance with ASX Listing Rule 17.2.

The voluntary suspension is requested pending an announcement by the Company to the market regarding a material licence agreement (“**purpose**”).


In accordance with ASX Listing Rule 17.2, the Company provides the following information in relation to the request:

1. The voluntary suspension is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose.
2. The Company requests that the voluntary suspension remains in place until the earlier of commencement of normal trading on Tuesday, 26 May 2020, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Tuesday, 26 May 2020.
4. The Company is not aware of any reason why the voluntary suspension should not be granted or of any further information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

Prescient Therapeutics Limited



Melanie Leydin
Company Secretary